RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles

Displaying items 1-12
  • The $84,000 hepatitis drug [Letter]

    It was interesting to read that there is now a cure for hepatitis C in the form of new drugs that are capable of completely suppressing the virus in 90 percent of patients in 8 to 12 weeks ("Gilead Sciences' $84,000 price for hepatitis drug is...
  • GLCCB to host forum on pre-exposure HIV treatment for at-risk populations

    GLCCB to host forum on pre-exposure HIV treatment for at-risk populations
    Local medical professionals will gather with members of Baltimore's gay community later this month to discuss a new medical treatment that involves HIV-negative patients taking a daily pill to avoid becoming infected. The April 28 forum, hosted by the...
  • HIV: we can and must get to zero [Commentary]

    HIV: we can and must get to zero [Commentary]
    The havoc that HIV can wreak on a family and a community can be devastating. Over the past three decades, we have watched helplessly as friends and family members died from HIV-related illnesses. Each one lived life brimming with hope and energy, prepared...
  • From intern to T. Rowe Price portfolio manager

    From intern to T. Rowe Price portfolio manager
    A decade ago, Taymour Tamaddon was an MBA. student with a background in physics trying to convince Baltimore-based money manager T. Rowe Price to hire him as an intern. Not only did Price give him the internship and hire him later as a health care...
  • FDA approves drug to prevent HIV infection

    FDA approves drug to prevent HIV infection
    The federal government has approved for the first time a drug that can prevent an HIV infection, a significant development for Baltimore where transmission rates for the virus remain high and growing. The U.S. Food and Drug Administration approved...
  • Singapore investor Temasek upbeat on China, seeks more bank, tech investments

    SINGAPORE (Reuters) - Singapore sovereign investor Temasek Holdings wants to increase its holdings in China's financial services and technology sectors, banking on the long-term growth prospects of the world's second largest economy. Temasek Holdings Pte...
  • How to fix a broken market in antibiotics

    How to fix a broken market in antibiotics
    The drugs don't work - and neither does the market, when it comes to antibiotics. When sophisticated bugs that medicines used to kill within days start to fight back and win, all of healthcare, and the people it keeps alive, is in trouble. Take...
  • Alejandro Galvis: Pharmaceuticals: Patent reform needed

    Sovaldi is used to treat and cure hepatitis C infection by inhibiting its replication. It has an effective cure rate on approximately 90 percent of the patients. The problem is that the cost of treating a person with Sovaldi is $84,000 for the 12 week...
  •  

     
     
     
  • New hepatitis C wonder drug shakes up the health care industry

    WASHINGTON When the harsh side effects of his hepatitis C medication forced Joel Roth to stop treatments last year, the only hope for his ailing liver was Sovaldi, a new wonder drug by Gilead Sciences Inc. that would hit the market later that year. In...
  • Merck to buy Idenix for $3.8B to boost hepatitis C drugs portfolio

    Merck & Co. Inc. said Monday it would buy Idenix Pharmaceuticals Inc for $3.85 billion and plans to combine the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C. Merck said it would pay $24.50 per share, more...
  • Health Insurers Propose Rate Increases For 2015 Coverage

    Insurance companies selling health plans next fall for coverage in 2015 are asking state regulators to approve prices that reflect medical-cost inflation, and, in some cases, federal mandates, and expensive drugs to treat Hepatitis C. Anthem Blue Cross...